| 2025-09-02 | +89.2% | expansion | Seeking Alpha | Mineralys Therapeutics launches $175M public offering |
| 2025-09-02 | +89.2% | news | Seeking Alpha | Mineralys surges after late-stage trial data AstraZenecas blood pressure drug |
| 2025-09-02 | +89.2% | news | Investor's Business Daily | Why AstraZeneca's Key Hypertension Rival Just Catapulted - Investor's Business Daily |
| 2025-03-10 | +39.4% | news | Seeking Alpha | Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts |
| 2025-03-10 | +39.4% | expansion | Seeking Alpha | Mineralys Therapeutics launches $250M public offering |
| 2025-03-10 | +39.4% | news | Seeking Alpha | Mineralys surges 53% on pivotal data for hypertension asset lorundrostat |
| 2025-03-10 | +39.4% | news | The Business Journals | Mineralys Therapeutics' stock price explodes after lorundrostat study results - The Business Journals |
| 2025-11-10 | +22.1% | earnings | Seeking Alpha | Mineralys Therapeutics GAAP EPS of -$0.52 beats by $0.10 |
| 2025-11-10 | +22.1% | news | StocksToTrade | Mineralys Stocks Fly on Positive News - StocksToTrade |
| 2024-08-13 | -21.5% | earnings | InvestorPlace | MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q2 2024 - InvestorPlace |
| 2025-11-08 | +15.5% | legal | Yahoo Finance | Why Mineralys Therapeutics (MLYS) Is Up After Positive Lorundrostat Phase 3 Data and FDA Filing Plans - Yahoo Finance |
| 2025-09-03 | +13.4% | news | Seeking Alpha | Mineralys: Soaring As Rival's Hypertension Data Falls Short - Buy The Next Dip |
| 2025-09-03 | +13.4% | news | Seeking Alpha | Mineralys Therapeutics prices upsized $250M stock offering |
| 2025-09-03 | +13.4% | news | Yahoo Finance | Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak - Yahoo Finance |
| 2025-09-03 | +13.4% | news | Quiver Quantitative | Mineralys Therapeutics Announces Upsized Public Offering of Common Stock Raising Approximately $250 Million - Quiver Quantitative |
| 2025-09-03 | +13.4% | news | Seeking Alpha | Mineralys: Soaring As Rival's Hypertension Data Falls Short - Buy The Next Dip (MLYS) - Seeking Alpha |
| 2025-03-11 | -12.1% | news | The Pharma Letter | Mineralys sees stock surge on lorundrostat data - The Pharma Letter |
| 2025-11-13 | -12.0% | executive | Investing.com | Mineralys Therapeutics CEO Congleton sells $9 million in stock - Investing.com |
| 2026-04-15 | +10.8% | news | Stock Titan | Mineralys (MLYS) CMO exercises options and sells 20,406 shares in 10b5-1 trades - Stock Titan |
| 2026-04-15 | +10.8% | executive | Stock Titan | Mineralys CEO sells 15,730 shares under 10b5-1 plan | MLYS Insider Trading - Stock Titan |
| 2026-04-15 | +10.8% | news | Stock Titan | David Rodman sells shares; Mineralys Therapeutics (NASDAQ: MLYS) Form 144 listing - Stock Titan |
| 2026-04-15 | +10.8% | news | Investing.com | Mineralys Therapeutics (MLYS) CMO Rodman sold $548k in shares - Investing.com |
| 2025-09-08 | +10.2% | news | Investing.com | Ra Capital Healthcare Fund buys Mineralys Therapeutics shares for $30m - Investing.com |
| 2026-04-14 | +10.0% | executive | Investing.com India | Mineralys therapeutics MLYS: Chief medical officer sells $59k in shares - Investing.com India |
| 2024-02-01 | +9.1% | analyst | eToro | MLYS Stock Price | Analyst Target 52.67 & Consensus - eToro |
| 2026-02-11 | -8.8% | news | Stock Titan | Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan |
| 2026-03-31 | +8.7% | executive | Proactive | Immunic appoints biopharmaceutical executive Jon Congleton to board |
| 2026-03-31 | +8.7% | earnings | MarketBeat | Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 12.4% - What's Next? - MarketBeat |
| 2026-03-31 | +8.7% | news | Stock Titan | Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares - Stock Titan |
| 2026-03-31 | +8.7% | news | Stock Titan | Mineralys Therapeutics (NASDAQ: MLYS) insider sells 3,000 shares - Stock Titan |
| 2025-09-05 | +8.5% | news | The Business Journals | Main Line firm raises $287.5 million in stock offering exceeding IPO - The Business Journals |
| 2026-04-08 | -7.2% | legal | simplywall.st | A Look At Mineralys Therapeutics (MLYS) Valuation After FDA Accepts Lorundrostat NDA For Hypertension - simplywall.st |
| 2026-04-08 | -7.2% | news | Stock Titan | Mineralys Therapeutics (NASDAQ: MLYS) details 2026 virtual meeting, board elections - Stock Titan |
| 2025-06-14 | -7.0% | news | simplywall.st | Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely? - simplywall.st |
| 2025-09-09 | +6.8% | news | Seeking Alpha | Mineralys Therapeutics, Inc. (MLYS) Presents at H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript |
| 2026-04-02 | +6.3% | news | Stock Titan | Mineralys Therapeutics (MLYS) director trades 3,000 shares under plan - Stock Titan |
| 2026-04-02 | +6.3% | news | simplywall.st | Is Mineralys Therapeutics (MLYS) Quietly Reframing Its Risk Profile With Senior Legal Hires? - simplywall.st |
| 2026-04-02 | +6.3% | executive | Investing.com | Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock - Investing.com |
| 2025-10-01 | +6.2% | news | Seeking Alpha | Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions |
| 2025-10-01 | +6.2% | news | Seeking Alpha | Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions (MLYS) - Seeking Alpha |
| 2026-03-09 | +6.2% | legal | Stock Titan | Blood pressure drug wins FDA review as apnea study shows no gain - Stock Titan |
| 2026-03-09 | +6.2% | legal | GlobeNewswire | Mineralys Therapeutics Announces FDA Acceptance of NDA for - GlobeNewswire |
| 2025-11-11 | +6.1% | earnings | Seeking Alpha | Mineralys outlines NDA submission timeline and advances lorundrostat trials amid expanded clinical focus |
| 2025-11-11 | +6.1% | earnings | Seeking Alpha | Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call Transcript |
| 2026-03-17 | -6.0% | news | Investing.com | Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 - Investing.com |
| 2026-03-17 | -6.0% | earnings | Stock Titan | Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan |
| 2023-08-15 | -5.9% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Mineralys Therapeutics, Inc. (MLYS) - Zacks Investment Research |
| 2026-03-16 | -5.8% | news | GlobeNewswire | Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-16 | -5.8% | news | Stock Titan | New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan |
| 2026-03-16 | -5.8% | news | Investing.com | Mineralys Therapeutics MLYS CMO sells shares worth $542,973 - Investing.com |
| 2026-03-16 | -5.8% | news | TradingView | Mineralys Therapeutics CMO Sells Over 20,000 Shares - TradingView |
| 2026-03-18 | -5.3% | news | TipRanks | Why Mineralys Therapeutics Shares Are Sliding Today - TipRanks |
| 2026-03-13 | -5.1% | legal | Insider Monkey | Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension |
| 2026-03-13 | -5.1% | news | Seeking Alpha | Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval |
| 2026-03-13 | -5.1% | legal | Yahoo Finance | Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension - Yahoo Finance |
| 2026-03-13 | -5.1% | analyst | Investing.com | Jefferies cuts Mineralys Therapeutics price target on drug concerns - Investing.com |
| 2026-03-13 | -5.1% | news | Seeking Alpha | Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha |
| 2024-03-18 | +5.1% | news | Seeking Alpha | Mineralys Therapeutics: A Story To Keep An Eye On (NASDAQ:MLYS) - Seeking Alpha |
| 2025-02-12 | +4.9% | news | Seeking Alpha | Mineralys outlines pivotal trial timelines for lorundrostat in hypertension |
| 2025-02-12 | +4.9% | earnings | Seeking Alpha | Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript |
| 2025-02-12 | +4.9% | news | Stock Titan | Mineralys Financial Results Reveal Strong Pipeline Progress: 3 Major Clinical Readouts Coming in 2025 - Stock Titan |
| 2025-03-12 | -4.8% | news | Seeking Alpha | Mineralys Therapeutics prices $175M stock offering |
| 2026-04-09 | -4.6% | news | Stock Titan | Mineralys Therapeutics (MLYS) Rule 144: Director sales and 2,170-share cashless exercise - Stock Titan |
| 2026-04-06 | +4.5% | executive | GlobeNewswire | Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors |
| 2026-04-06 | +4.5% | news | Xã Thanh Hà | Can Mineralys Therapeutics (MLYS) Stock Recover Now | Price at $28.23, Up 4.67% - ATR Levels - Xã Thanh Hà |
| 2024-02-09 | +4.4% | news | The Business Journals | Mineralys Therapeutics set to raise $120M from investors to develop treatment for high blood pressure - The Business Journals |
| 2024-05-11 | -4.4% | earnings | MarketBeat | Mineralys Therapeutics (MLYS) Stock Forecast and Price Target 2026 - MarketBeat |
| 2026-03-12 | -4.3% | expansion | Seeking Alpha | Mineralys targets December 2026 lorundrostat approval as payer engagement and data drive launch strategy |
| 2026-03-12 | -4.3% | earnings | Seeking Alpha | Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript |
| 2026-03-12 | -4.3% | earnings | Seeking Alpha | Mineralys Therapeutics GAAP EPS of -$0.40 beats by $0.13 |
| 2026-03-12 | -4.3% | legal | Stock Titan | Experimental hypertension drug lorundrostat heads for FDA decision in Dec. 2026 - Stock Titan |
| 2026-03-12 | -4.3% | earnings | TradingView | Mineralys Therapeutics 10-K: $0 Revenue, $(2.29) EPS - TradingView |
| 2026-04-07 | -4.3% | legal | Simply Wall St. | Does Mineralys Therapeutics’ (MLYS) FDA Progress and Legal Hire Reshape Its Cardiorenal Commercialization Strategy? |
| 2026-04-07 | -4.3% | executive | Motley Fool | Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock? |
| 2026-04-07 | -4.3% | executive | The Motley Fool | Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock? - The Motley Fool |
| 2026-04-07 | -4.3% | legal | Yahoo Finance | Does Mineralys Therapeutics’ (MLYS) FDA Progress and Legal Hire Reshape Its Cardiorenal Commercialization Strategy? - Yahoo Finance |
| 2025-08-13 | +4.2% | earnings | Seeking Alpha | Mineralys signals pre-NDA meeting for lorundrostat in Q4 2025 while expanding clinical programs into cardiorenal comorbidities |
| 2025-08-13 | +4.2% | earnings | Seeking Alpha | Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript |
| 2026-04-03 | +4.2% | executive | Investing.com Australia | Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock By Investing.com - Investing.com Australia |
| 2026-04-21 | -4.1% | news | Stock Titan | Mineralys (MLYS) CMO logs small 10b5-1 share sale and option exercise - Stock Titan |
| 2026-01-30 | -4.0% | news | Yahoo Finance | Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones - Yahoo Finance |
| 2026-03-24 | +3.9% | executive | GlobeNewswire | Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer |
| 2026-03-24 | +3.9% | news | Stock Titan | Mineralys brings in veteran biotech lawyer as it advances lorundrostat - Stock Titan |
| 2026-03-24 | +3.9% | executive | GlobeNewswire | Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer - GlobeNewswire |
| 2026-03-11 | -3.4% | legal | Yahoo Finance | Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - Yahoo Finance |
| 2025-08-05 | +3.0% | executive | simplywall.st | Mineralys Therapeutics CFO & Secretary Adam Levy Sells 36% Of Holding - simplywall.st |
| 2026-03-10 | +3.0% | legal | Seeking Alpha | Mineralys spikes as blood pressure drug undergoes FDA review |
| 2026-03-10 | +3.0% | analyst | Investing.com | Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data - Investing.com |
| 2026-03-10 | +3.0% | legal | Seeking Alpha | Mineralys spikes as blood pressure drug undergoes FDA review - Seeking Alpha |
| 2026-03-10 | +3.0% | analyst | Investing.com | H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance - Investing.com |
| 2025-09-13 | -2.9% | M&A | Seeking Alpha | SA Asks: Which biotechs could be acquired by year's end? |
| 2026-04-17 | -2.6% | news | Stock Titan | 416-share cashless exercise reported by Mineralys (NASDAQ: MLYS) - Stock Titan |
| 2026-03-20 | +2.3% | news | Simply Wall St. | Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? |
| 2026-03-20 | +2.3% | news | Yahoo Finance | Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance |
| 2026-01-13 | +2.0% | executive | Investing.com | Mineralys Therapeutics CEO Congleton sells $529k in MLYS stock - Investing.com |
| 2024-04-11 | +2.0% | analyst | TradingView | MLYS Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-09-28 | -1.9% | news | Seeking Alpha | Goldman's 48 potential M&A candidates |
| 2025-09-21 | -1.7% | news | TradingView | MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView |
| 2025-09-21 | -1.7% | news | The Motley Fool | These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? - The Motley Fool |
| 2025-09-21 | -1.7% | news | NAI500 | Miracle or Bubble? These 2 Healthcare Stocks Doubled in Less Than a Month - NAI500 |
| 2025-06-03 | -1.7% | news | Seeking Alpha | Mineralys Therapeutics: Merits A Small 'Speculative' Holding |
| 2025-06-03 | -1.7% | news | Seeking Alpha | Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS) - Seeking Alpha |
| 2023-04-29 | +1.7% | news | Zacks Investment Research | Should I buy Mineralys Therapeutics, Inc. (MLYS) - Zacks Investment Research |
| 2026-04-18 | -1.5% | news | Xã Vĩnh Công | Mineralys Therapeutics (MLYS) Stock: Why Pricing Increase (Idled) 2026-04-18 - Expert Insights - Xã Vĩnh Công |
| 2025-08-12 | +1.4% | earnings | Seeking Alpha | Mineralys Therapeutics GAAP EPS of -$0.66 beats by $0.10 |
| 2026-04-01 | -1.3% | news | Insider Monkey | Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress |
| 2026-04-01 | -1.3% | news | Yahoo Finance | Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress - Yahoo Finance |
| 2025-12-23 | -1.2% | news | The Motley Fool | Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears - The Motley Fool |
| 2026-01-06 | -1.1% | news | Stock Titan | New blood pressure drug shows promise for hard-to-treat patients - Stock Titan |
| 2026-02-16 | +1.1% | news | Yahoo Finance | Is Mineralys Therapeutics (MLYS) Pricing Reflect The Recent Share Price Pullback - Yahoo Finance |
| 2026-04-16 | -0.9% | executive | Investing.com South Africa | Congleton, Mineralys Therapeutics CEO, sells $421k in MLYS stock By Investing.com - Investing.com South Africa |
| 2025-11-14 | +0.9% | executive | Investing.com Nigeria | Mineralys therapeutics (MLYS) CFO Adam Levy sells $5.36m in stock - Investing.com Nigeria |
| 2025-11-14 | +0.9% | earnings | TipRanks | Mineralys Therapeutics’ Stock Dips Amid Earnings Miss - TipRanks |
| 2023-02-11 | -0.6% | earnings | MarketBeat | Mineralys Therapeutics (MLYS) Stock Price, News & Analysis - MarketBeat |
| 2023-02-11 | -0.6% | earnings | MarketBeat | Top Mineralys Therapeutics (MLYS) Competitors 2026 - MarketBeat |
| 2023-02-11 | -0.6% | earnings | MarketBeat | Mineralys Therapeutics (MLYS) Earnings Date and Reports 2026 - MarketBeat |
| 2025-12-28 | -0.5% | news | Seeking Alpha | Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 |
| 2025-12-28 | -0.5% | news | Seeking Alpha | Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 (NASDAQ:MLYS) - Seeking Alpha |
| 2025-09-15 | +0.5% | news | simplywall.st | Assessing Mineralys Therapeutics After Its 155% Surge and Strong Pipeline Developments - simplywall.st |
| 2026-04-13 | +0.4% | news | Stock Titan | Mineralys (MLYS) CMO exercises options and sells 2,170 shares under 10b5-1 plan - Stock Titan |
| 2026-04-13 | +0.4% | executive | Investing.com | Mineralys therapeutics MLYS: Chief medical officer sells $59k in shares - Investing.com |
| 2026-04-13 | +0.4% | news | Stock Titan | Affiliate sale of 14,058 shares and multiple David Rodman trades (MLYS) - Stock Titan |
| 2026-04-13 | +0.4% | earnings | MarketBeat | Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,170 Shares - MarketBeat |
| 2026-04-13 | +0.4% | news | Stock Titan | Mineralys Therapeutics (NASDAQ: MLYS) insider sales and RSU vesting disclosed - Stock Titan |
| 2025-05-12 | -0.3% | earnings | Seeking Alpha | Mineralys Therapeutics GAAP EPS of -$0.79 beats by $0.17 |
| 2025-05-13 | -0.1% | earnings | Seeking Alpha | Mineralys plans NDA submission for lorundrostat following pivotal hypertension data and $201M equity raise |
| 2025-05-13 | -0.1% | earnings | Seeking Alpha | Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript |
| 2026-04-26 | — | executive | Insider Monkey | Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer |
| 2026-04-26 | — | executive | Yahoo Finance | Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer - Yahoo Finance |
| 2026-04-26 | — | executive | Insider Monkey | Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer - Insider Monkey |
| 2026-04-24 | — | news | MEXC Exchange | MLYS Price Today: Mineralys Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange |